Hou Yun, Wang Hua-qing, Fu Kai, Zhang Hui-lai, Qian Zheng-zi, Qiu Li-hua, Li Wei, Zhou Shi-yong, Li Lan-fang, Hao Xi-shan
Cancer Hospital, Tianjin Medical University, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):911-5.
The aim of this study was to assess the expression of cell division cycle 7 (Cdc7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients.
Clinical data of 60 DLBCL patients treated in our hospital from 2008.1 to 2010.1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients.
The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38.3% and those with low expression 65.4% (P = 0.001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37.2% and those with low expression was 75.5% (P = 0.032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44.0% and those with low expression was 68.2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39.0% and those with low expression was 63.4% (P = 0.007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2.
Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.
本研究旨在评估细胞分裂周期7（Cdc7）激酶和微小染色体维持蛋白2（MCM2）在弥漫性大B细胞淋巴瘤（DLBCL）中的表达情况，并探讨它们与DLBCL患者预后的关系。
收集2008年1月至2010年1月在我院接受治疗的60例DLBCL患者的临床资料。采用实时PCR法测定外周血和骨髓中Cdc7和MCM2的表达水平。进行统计学分析以评估它们与DLBCL患者预后的相关性。
外周血Cdc7高表达患者的2年生存率为38.3%，低表达患者为65.4%（P = 0.001）。骨髓Cdc7高表达患者的2年生存率为37.2%，低表达患者为75.5%（P = 0.032）。外周血MCM2高表达患者的2年生存率为44.0%，低表达患者为68.2%（P = 0.025）。骨髓MCM2高表达患者的2年生存率为39.0%，低表达患者为63.4%（P = 0.007）。Cdc7和MCM2高水平表达的DLBCL患者的疾病特异性生存率较差。
Cdc7和MCM2的表达可用于评估肿瘤增殖，并且在与传统标志物联合预测DLBCL患者的预后时可能作为一个额外的标志物。此外，Cdc7和MCM2信号通路可能作为治疗难治性DLBCL淋巴瘤患者的一种新方法。
